Agios Pharmaceuticals

AGIO · NASDAQ

$36.64+$1.74 (+4.99%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $34.90

AGIO analyst rating

BuyConsensus of 9 analysts over the last 12 months. 67% rate it a buy.

Strong buy0
Buy6
Hold3
Underperform0
Sell0

12-month price target · 10 analysts

Average $48.96 (+33.6% upside)

Low: $32.32
Now: $36.64
High: $76.65

Upgrades and downgrades

The latest rating actions, newest first

AGIO analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Truist Securities	Oct 7, 2026	Maintains	Buy	$39.00 → $37.00	47%
B of A Securities	Sep 21, 2026	Maintains	Buy	$46.00 → $50.00	36%
JP Morgan	Aug 7, 2026	Maintains	Neutral	$31.00 → $34.00	44%
Citigroup	Jul 31, 2026	Maintains	Buy	$46.00 → $52.00	36%
Truist Securities	Jul 31, 2026	Maintains	Buy	$41.00 → $39.00	47%
HC Wainwright & Co.	Jul 30, 2026	Maintains	Buy	$52.00 → $55.00	27%
HC Wainwright & Co.	Jul 21, 2026	Maintains	Buy	$54.00 → $52.00	27%
RBC Capital	Jul 7, 2026	Maintains	Sector Perform	$28.00 → $32.00	44%
Truist Securities	Jul 7, 2026	Maintains	Buy	$36.00 → $41.00	47%
B of A Securities	Jul 7, 2026	Maintains	Buy	$40.00 → $46.00	36%

The case for and against

Updated Oct 21, 2026

Bull case

Agios Pharmaceuticals is well positioned by a de-risked, multi-asset hematology franchise anchored by mitapivat, which already has approvals in pyruvate kinase deficiency and thalassemia and is advancing in sickle cell disease through an FDA-accepted sNDA under Priority Review with a Nov 1 PDUFA date. The regulatory setup is attractive because accelerated approval could make mitapivat the first oral PK activator in SCD, while a confirmatory REIGNITE Phase 3 trial is planned for August 2026 to support broader labeling and longer-term value creation. Financially, 1Q26 revenues of $20.7M beat estimates, non-GAAP EPS was ($1.69), and the company ended with about $1B in cash, supporting continued R&D across tebapivat, AG-181, AG-236, and other pipeline programs.

Bear case

Agios Pharmaceuticals is exposed to significant fundamental risk because its value depends heavily on mitapivat and a narrow set of assumed pipeline outcomes, while other assets and indications are not included in the valuation. The company also faces meaningful clinical, regulatory, and commercial uncertainty, including the possibility of safety signals, failed statistical significance, stronger-than-expected competition, and adverse decisions on its programs. Financially, the outlook is pressured by liquidity and concentration risk, and the analysis uses a 10% discount rate and a -25% terminal growth rate over estimates extended to 2038, underscoring how fragile long-term expectations can be.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.